Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1
Holding DE:6C1?
Track your performance easily
6C1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.78 - €4.40
Previous Close€1.03
Volume0.00
Average Volume (3M)9.11K
Market Cap
€82.53M
Enterprise Value-€19.34M
Total Cash (Recent Filing)$117.59M
Total Debt (Recent Filing)$10.60M
Price to Earnings (P/E)6.1
Beta0.38
Next Earnings
Feb 26, 2025EPS Estimate
-€0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding78,258,879
10 Day Avg. Volume1,144
30 Day Avg. Volume9,112
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-3.45
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit-0.19
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
€3.26Price Target Upside215.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CytomX Therapeutics News
PremiumCompany Announcements
CytomX Therapeutics Reports Q3 Progress and Growth
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe CX-801 Phase 1 trial has commenced patient dosing, focusing on evaluating safety and clinical activity for potential broad applications in cancer treatment.
Financial PerformanceCytomX reported a net profit of $0.07 per share, surpassing prior estimates of a net loss of $0.09 per share.
Revenue GrowthCytomX recorded $33.4 million in revenue, significantly exceeding the most recent estimate of $25.0 million.
Bears Say
Clinical RisksThe emergence of unexpected side-effects with CX-904, CX-2051, CX-801, or probody T-cell bispecifics poses significant risks in future clinical data.
Pancreatic Cancer Development ChallengesDevelopment in pancreatic cancer has historically faced numerous clinical challenges, presenting a potential hurdle for the company's success.
Pipeline Validation UncertaintyThe lack of a current price target on CTMX shares highlights uncertainty, as further clinical validation of the company's pipeline assets is awaited.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.69% Insiders
7.89% Mutual Funds
35.89% Other Institutional Investors
49.12% Public Companies and
Individual Investors
6C1 FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was €0.78 and its highest was €4.40 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
Currently, no data Available
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 67 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported €0.068 earnings per share for the quarter, beating the consensus estimate of -€0.166 by €0.233.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -€0.19.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 78,258,880 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of €0.068 in its last earnings report, beating expectations of -€0.166. Following the earnings report the stock price went up 20.119%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Among the largest hedge funds holding CytomX Therapeutics Inc’s share is Woodline Partners LP. It holds CytomX Therapeutics Inc’s shares valued at 465K.
---
CytomX Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.26 (215.40% Upside)
€3.26 (215.40% Upside)
Blogger Sentiment
Bullish
DE:6C1 Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.16%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
---
6C1 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment. While there were significant achievements in revenue growth, pipeline progress, and strong collaborations, there were also concerns over increased expenses and delays in key clinical decisions.Read More>---
6C1 Stock 12 Month Forecast
Average Price Target
€3.26
▲(215.40% Upside)
Technical Analysis
Fate Therapeutics
―
Mersana Therapeutics
―
Karyopharm Therapeutics
―
Scholar Rock Holding
―
Alnylam Pharma
―
Best Analysts Covering 6C1
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-12.99%
reiterated a buy rating 4 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.99% per trade.
---